Founders
Andrea Califano Ph.D.; Founding Director, Columbia Initiative in Systems Biology, Director Center for the Multiscale Analysis of Genetic and Celllular Networks; Associate Director, Herbert Irving Comprehensive Cancer Center, Columbia University.
Dr. Califano is an internationally recognized leader in computational biology and, specifically, in cancer systems biology. He has more than 20 years of experience in both industry and academia. Since 2003, he has been Professor of Biomedical Informatics aat Columbia University, where he was recently appointed as Founding Director of the Columbia Initiative in Systems Biology, an organization that includes the Center for Computational Biology and Bioinformatics (C2B2) and the Columbia Genome Center (CGC). He also directs MAGNet, one of seven NIH-funded National Centers for Biomedical Computing. Since 1998, he has been especially active in the development of systems biology methods for the dissection of dysregulated pathways in human malignancies.
Riccardo Dalla-Favera M.D.; Director, Herbert Irving Comprehensive Cancer Center, Columbia University.
Dr. Dalla-Favera is the author of more than 250 peer reviewed publications and an internationally recognized leader in cancer research. His most significant contributions are in the study of non-Hodgkins lymphomas. His discoveries in this field represent a significant fraction of the current knowledge on the mechanisms and genes involved in the pathogenesis of these diseases. Dr. Dalla-Favera received his M.D. from the University of Milan in 1976. His experience includes work at the Laboratory of Tumor Cell Biology at The National Cancer Institute, where he initiated pioneering studies on the cloning of human proto-oncogenes and their role in the pathogenesis of cancer.
Owen A. O’Connor MD, Ph.D.; Professor of Medicine and Pharmacology, Deputy Cancer Director, NYU Cancer Institute; Chief, Division of Hematologic Malignancies and Medical Oncology, NYU Langone Medical Center, New York, NY
Dr. O’Connor is and internationally recognized leader in the discovery and development of new drugs for the treatment of hematologic malignancies, in particular lymphoma. To date his laboratory and clinical research efforts have led to the U.S. FDA approval of several drugs for the treatment of lymphoma, including the proteasome inhibitor bortezomib for the treatment of mantle cell lymphoma, the histone deacetylase inhibitor vorinostat for the treatment of cutaneous T-cell lymphoma (CTCL), and most recently pralatrexate, the first drug ever approved for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). He has published more than 100 articles in numerous journals and maintains an active research program focused on small molecule development and early phase clinical trials.
Board of Directors
Tamas Bartfai Ph.D.; Chair of the Molecular and Integrative Neurosciences Department at the Scripps Research Institute, La Jolla California
Dr. Bartfai has been serving as consultant, senior consultant, SAB member and Sr VP (Hoffmann La Roche, Basel) in pharmaceutical industry (Astra ( 1975-95, Novartis (2000-2007, Lily, Pfizer2007- ), biotech industry, and venture capital industry since 1975. He has been involved in the development of vaccines, recombinant proteins and small molecule drugs. He has been a professor of the Karolinska Institute, Stockholm University, and serves as adjunct professor at Rockefeller University, Stanford University. He is a member of several academies.
Andrea Califano Ph.D.; Founding Director, Columbia Initiative in Systems Biology, Director Center for the Multiscale Analysis of Genetic and Celllular Networks; Associate Director, Herbert Irving Comprehensive Cancer Center, Columbia University.
Dr. Califano is an internationally recognized leader in computational biology and, specifically, in cancer systems biology. He has more than 20 years of experience in both industry and academia. Since 2003, he has been Professor of Biomedical Informatics aat Columbia University, where he was recently appointed as Founding Director of the Columbia Initiative in Systems Biology, an organization that includes the Center for Computational Biology and Bioinformatics (C2B2) and the Columbia Genome Center (CGC). He also directs MAGNet, one of seven NIH-funded National Centers for Biomedical Computing. Since 1998, he has been especially active in the development of systems biology methods for the dissection of dysregulated pathways in human malignancies.
Stephan Catsicas Ph.D.; Chairman, Tilocor Life Sciences
Stefan Catsicas received a PhD in Neurosciences from the University of Lausanne (Switzerland) and did postdoctoral work at the Research institute of Scripps Clinic (San Diego, USA). He managed the research and preclinical development programs in Neurosciences at the Glaxo Research Institute (Geneva, Switzerland) and served as Professor and Chairman of Cellular Biology at the school of Medicine in Lausanne. He was then appointed Vice-President, Research Director and Professor of Cellular Engineering at the Swiss Federal Institute of Technology in Lausanne (EPFL). In addition to his academic activities, Stefan Catsicas has promoted and advised investment funds and biotechnology companies in Europe and in the United States. He is one of the founders of Tilocor Life Science and has resigned from his academic duties to chair the group's activities.
Riccardo Dalla-Favera M.D.; Director, Herbert Irving Comprehensive Cancer Center, Columbia University.
Dr. Dalla-Favera is author of more than 250 peer reviewed publications and an internationally recognized leader in cancer research. His most significant contributions are in the study on non-Hodgkins lymphomas. His discoveries in this field represent a significant fraction of the current knowledge on the mechanisms and genes involved in the pathogenesis of these diseases. Dr. Dalla-Favera received his M.D. from the University of Milan in 1976. His experience includes work at the Laboratory of Tumor Cell Biology at The National Cancer Institute, where he initiated pioneering studies on the cloning of human proto-oncogenes and their role in the pathogenesis of cancer.
Owen A. O’Connor MD, Ph.D.; Professor of Medicine and Pharmacology, Deputy Cancer Director, NYU Cancer Institute; Chief, Division of Hematologic Malignancies and Medical Oncology, NYU Langone Medical Center, New York, NY
Dr. O’Connor is and internationally recognized leader in the discovery and develoment of new drugs for the treatment of hematologic malignancies, in particular lymphoma. To date his laboratory and clinical research efforts have led to the U.S. FDA apporval of several drugs for the treament of lymphoma, including the proteasome inhibitor bortezomib for the treatment of mantle cell lymphoma, the histone deacetylase inhibitor vorinostat for the treatment of cutaneous T-cell lymphoma (CTCL), and most recently pralatrexate, the first drug ever approved for the treament of relapsed or refractory peripheral T-cell lymphoma (PTCL). He has published more than 100 articles in numerous journals and maintains an active research program focused on small molecule development and early phase clinical trials.
